Last reviewed · How we verify
BNT162b2 Bivalent (WT/OMI BA.4/BA.5) (bnt162b2-bivalent-wt-omi-ba-4-ba-5)
At a glance
| Generic name | bnt162b2-bivalent-wt-omi-ba-4-ba-5 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
- Injection site pain (PAIN)
- Fatigue (FATIGUE)
- Headache (HEADACHE)
- Myalgia (MUSCLE PAIN)
- Chills (CHILLS)
- Arthralgia (JOINT PAIN)
- Diarrhoea (DIARRHEA)
- Injection site swelling (SWELLING)
- Injection site erythema (REDNESS)
- COVID-19
- Pyrexia (FEVER)
- Vomiting (VOMITING)
Key clinical trials
- A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT162b2 Bivalent (WT/OMI BA.4/BA.5) CI brief — competitive landscape report
- BNT162b2 Bivalent (WT/OMI BA.4/BA.5) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI